OBJECTIVETo study the clinicopathologic features of small cell carcinoma of ovary, hypercalcemic type (SCCOHT) and to evaluate the diagnostic significance of loss of SMARCA4 expression.

METHODSThe clinicopathologic characteristics of 5 cases of SCCOHT were reviewed. The expression of SMARCA4 protein was detected by immunohistochemistry in the cases of SCCOHT and 240 cases of other primary malignant tumors of ovary and peritoneum.

RESULTSThe mean and medium age of these patients was 30 years and 28 years, respectively. The presenting symptoms included abdominal pain, distention and a pelvic mass. Hypercalcemia was found in 3 patients. The maximum diameter of tumors ranged from 13.5 to 22.0 cm. Extraovarian spread was demonstrated in all of the patients on presentation. Histologically, the tumors were composed of closely packed small round cells with scanty cytoplasm, hyperchromatic nuclei and irregular chromatin clumps. The tumor cells grew in sheets, nests, cords or trabecular pattern. Follicle-like spaces were observed in 4 cases. Three of the tumors contained large cells with abundant eosinophilic cytoplasm. Spindle cell morphology was found in 1 case. There were 2 cases with myxoid or hyaline stroma. Four out of five of SCCOHT cases showed loss of SMARCA4 protein while only 6.3% (15/240) of the other primary malignant tumors of ovary and peritoneum , including undifferentiated carcinoma (1/5), high-grade serous carcinoma (4.6%, 5/109), endometrioid carcinoma (7.7%, 2/26), clear cell carcinoma (1/9), mucinous carcinoma (1/5), mixed carcinoma (4.9%, 3/61), carcinosarcoma (1/9) and high-grade serous carcinoma of peritoneum (1/9), were negative.

CONCLUSIONSSCCOHT is a rare malignant tumor and often misdiagnosed as other types of ovarian small cell tumor. Loss expression of SMARCA4 protein is characteristic and facilitates the diagnosis and differential diagnosis of SCCOHT.

Adenocarcinoma, Mucinous ; Adult ; Carcinoma, Small Cell ; genetics ; metabolism ; pathology ; DNA Helicases ; genetics ; metabolism ; Female ; Humans ; Hypercalcemia ; pathology ; Immunohistochemistry ; Neoplasms, Glandular and Epithelial ; genetics ; metabolism ; pathology ; Nuclear Proteins ; genetics ; metabolism ; Ovarian Neoplasms ; genetics ; metabolism ; pathology ; Transcription Factors ; genetics ; metabolism

OBJECTIVETo investigate neuroendocrine differentiation and its mechanism in ovarian epithelial tumors.

METHODSNeuroendocrine (NE) cells were identified by immunohistochemical staining for chromogranin A and synaptophysin in 79 cases of ovarian epithelial tumor and 22 cases of normal ovary. Double-labeling technique was used for simultaneous detection of CgA and epithelial membrane antigean (EMA), and the staining intensity was quantitatively evaluated using an image analysis system.

RESULTSThe positive staining rate for CgA and SYN in ovarian epithelial tumors was 59.4% and 65.36%, respectively, which was higher than that in normal ovary (P=0.000), in which numerous NE cells were found. Both the number and staining intensity of NE cells in ovarian epithelial tumor were increased as compared with normal ovary. Cells co-expressing CgA and EMA were detected in the ovarian epithelial tumors.

CONCLUSIONThe presence of NE cells in ovarian epithelial tumor suggests heterogeneity of the tumors, and the occurrence of "multidirectional differentiation cells" within the these tumors indicates that NE cells might derive from malignant cells with multidirectional differentiation capacity.

Adult ; Aged ; Case-Control Studies ; Cell Differentiation ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Immunohistochemistry ; Middle Aged ; Neoplasms, Glandular and Epithelial ; genetics ; metabolism ; pathology ; Neuroendocrine Cells ; metabolism ; pathology ; Ovarian Neoplasms ; genetics ; metabolism ; pathology ; Ovary ; cytology ; metabolism ; pathology ; Young Adult

Adenocarcinoma, Clear Cell ; etiology ; pathology ; Brenner Tumor ; etiology ; pathology ; Carcinosarcoma ; etiology ; pathology ; Cell Transformation, Neoplastic ; Cystadenocarcinoma, Serous ; etiology ; pathology ; Epithelial Cells ; metabolism ; pathology ; Female ; Genes, p53 ; Humans ; Mutation ; Neoplasms, Glandular and Epithelial ; etiology ; genetics ; metabolism ; pathology ; Ovarian Neoplasms ; etiology ; genetics ; metabolism ; pathology ; Tumor Suppressor Protein p53 ; genetics ; metabolism

PURPOSE: Both genetic and epigenetic alterations can lead to abnormal expression of metastasis-regulating genes in tumor cells. Recent studies suggest that aberrant epigenetic alterations, followed by differential gene expression, leads to an aggressive cancer cell phenotype. We examined epigenetically regulated genes that are involved in ovarian cancer metastasis. MATERIALS AND METHODS: We developed SK-OV-3 human ovarian carcinoma cell xenografts in mice. We compared the mRNA expression and DNA methylation profiles of metastatic tissues to those of the original SK-OV-3 cell line. RESULTS: Metastatic implants showed increased mRNA expression of the carbonic anhydrase 9 (CA9) gene and hypomethylation at CpG sites in the CA9 promoter. Treatment of wild-type SK-OV-3 cells with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine reduced methylation of the CA9 promoter and increased CA9 mRNA expression. Eight CpGs, which were located at positions -197, -74, -19, -6, +4, +13, +40, and +86, relative to the transcription start site, were hypomethylated in metastatic tumor implants, compared to that of wild-type SK-OV-3. Overexpression of CA9 induced an aggressive phenotype, including increased invasiveness and migration, in SK-OV-3 cells. CONCLUSION: Alterations in the DNA methylation profile of the CA9 promoter were correlated with a more aggressive phenotype in ovarian cancer cells.
Animals ; Azacitidine/*analogs & derivatives/pharmacology ; Carbonic Anhydrases/metabolism ; *DNA Methylation ; Female ; Gene Expression Regulation, Neoplastic/*drug effects ; Humans ; Mice ; Neoplasm Invasiveness/genetics ; Neoplasm Metastasis/genetics/*pathology ; Neoplasms, Experimental ; Neoplasms, Glandular and Epithelial/genetics/*metabolism/pathology ; Ovarian Neoplasms/genetics/*metabolism/pathology ; Phenotype ; Promoter Regions, Genetic ; RNA, Messenger/metabolism

OBJECTIVETo study the expression and clinical significance of kidney injury molecule-1 (KIM-1) in primary and metastatic renal epithelial neoplasms.

METHODSA total of 136 cases of kidney neoplasms were retrospectively reviewed including 63 primary clear cell renal cell carcinomas (RCCs), 22 papillary RCCs, 13 chromophobe RCCs, 7 oncocytomas, 7 RCCs associated with Xp11.2 translocation/TFE3 gene fusions and 24 metastatic clear cell RCCs. Immunostaining for KIM-1 and kidney-specific-protein (Ksp)-cadherin were performed and the relationship to tumor stage and grade in clear cell RCCs was investigated.

RESULTSExpression of KIM-1 was detected in 77.8% (49/63) of clear cell RCCs, 90.9% (20/22) of papillary RCCs, 1/13 of chromophobe RCCs, 7/7 of RCCs associated with Xp11.2 translocation/TFE3 gene fusions and 87.5%(21/24) of the metastatic RCCs, but not detected in 7 cases of oncocytomas. A diffuse expression of KIM-1 was more frequently observed in Furhman nuclear grade III/IV clear cell RCCs (P = 0.010). Ksp-cadherin expression was mainly observed in chromophobe RCCs and oncocytomas.

CONCLUSIONSKIM-1 is a specific biomarker for injuried kidney proximal tubules and the corresponding neoplasms, and has a high specificity and sensitivity for primary or metastatic clear cell RCCs, papillary RCCs and RCCs associated with Xp11.2 translocation/TFE3 gene fusions. Combination of KIM-1 and Ksp-cadherin immunostaining can lead to a more precise histological classification of primary kidney epithelial neoplasms and improve the diagnostic accuracy of metastatic RCCs.

Adenoma, Oxyphilic ; metabolism ; pathology ; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors ; genetics ; metabolism ; Bone Neoplasms ; metabolism ; secondary ; Cadherins ; metabolism ; Carcinoma, Papillary ; metabolism ; pathology ; Carcinoma, Renal Cell ; genetics ; metabolism ; pathology ; Chromosomes, Human, X ; Gene Fusion ; Hepatitis A Virus Cellular Receptor 1 ; Humans ; Kidney Neoplasms ; genetics ; metabolism ; pathology ; Lung Neoplasms ; metabolism ; secondary ; Membrane Glycoproteins ; metabolism ; Neoplasms, Glandular and Epithelial ; classification ; genetics ; metabolism ; pathology ; Receptors, Virus ; metabolism ; Retrospective Studies ; Translocation, Genetic

OBJECTIVE: We aimed to evaluate the prognostic and predictive value of the nucleotide excision repair-related gene GTF2H5, which is localized at the 6q24.2-26 deletion previously reported by our group to predict longer survival of high-grade serous ovarian cancer patients. METHODS: In order to test if protein levels of GTF2H5 are associated with patients' outcome, we performed GTF2H5 immunohistochemical staining in 139 high-grade serous ovarian carcinomas included in tissue microarrays. Upon stratification of cases into high- and low-GTF2H5 staining categories (> and < or = median staining, respectively) Kaplan-Meier and log-rank test were used to estimate patients' survival and assess statistical differences. We also evaluated the association of GTF2H5 with survival at the transcriptional level by using the on-line Kaplan-Meier plotter tool, which includes gene expression and survival data of 855 high-grade serous ovarian cancer patients from 13 different datasets. Finally, we determined whether stable short hairpin RNA-mediated GTF2H5 downregulation modulates cisplatin sensitivity in the SKOV3 and COV504 cell lines by using cytotoxicity assays. RESULTS: Low expression of GTF2H5 was associated with longer 5-year survival of patients at the protein (hazard ratio [HR], 0.52; 95% CI, 0.29 to 0.93; p=0.024) and transcriptional level (HR, 0.80; 95% CI, 0.65 to 0.97; p=0.023) in high-grade serous ovarian cancer patients. We confirmed the association with 5-year overall survival (HR, 0.55; 95% CI, 0.38 to 0.78; p=0.0007) and also found an association with progression-free survival (HR, 0.72; 95% CI, 0.54 to 0.96; p=0.026) in a homogenous group of 388 high-stage (stages III-IV using the International Federation of Gynecology and Obstetrics staging system), optimally debulked high-grade serous ovarian cancer patients. GTF2H5-silencing induced a decrease of the half maximal inhibitory concentration upon cisplatin treatment in GTF2H5-silenced ovarian cancer cells. CONCLUSION: Low levels of GTF2H5 are associated with enhanced prognosis in high-grade serous ovarian cancer patients and may contribute to cisplatin sensitization.
Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor/biosynthesis/genetics ; Cystadenocarcinoma, Serous/*genetics/metabolism/pathology ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Kaplan-Meier Estimate ; Middle Aged ; Neoplasm Grading ; Neoplasm Proteins/biosynthesis/genetics ; Neoplasms, Glandular and Epithelial/*genetics/metabolism/pathology ; Ovarian Neoplasms/*genetics/metabolism/pathology ; Prognosis ; Transcription Factors/biosynthesis/*genetics ; Tumor Cells, Cultured

OBJECTIVETo investigate the effect of CXCL1 gene expression on biological function of ovarian cancer cells and its mechanism of action.

METHODSRT-PCR was used to amplify the full-length sequence of CXCL1, which was used to construct the recombinant lentiviral plasmids, and then the plasmids were packaged with human renal epithelial cell line 293T cells, and the ovarian cancer 2780 cells were transfected with CXCL1 gene by virus supernatant particles. The expression of CXCL1 mRNA and protein in 2780 cells with lentivirus-mediated CXCL1expression were determined by RT-PCR and ELISA, respectively. The growth curve, cell cycle and colony formation in vitro were measured by MTT assay, flow cytometry and colony formation counting, respectively. The cell invasion and migration in vitro was detected by Transwell chambers and migration attack methods, respectively.

RESULTSThe sequencing results showed that the recombinant lentiviral plasmid of CXCL1-pWPI had 100% homology with the CXCL1 gene, identified by BLAST analysis. RT-PCR and ELISA results showed positive expression of CXCL1 mRNA and protein in the CXCL1-PWPI group. The doubling time of the CXCL1-PWPI group was significantly shorter than that in the A2780 and PWPI groups (P < 0.05). The rate of colony-formation in the CXCL1-PWPI group was also significantly higher than that of the A2780 and PWPI groups (P < 0.05). The proportion of cells in G1 phase (44.0%) in the CXCL1-PWPI group was also significantly lower compared with that in the PWPI and A2780 groups (61.4% and 62.7%), with a significant difference (P < 0.001). There was no significant difference between the cell migration capacity (P > 0.05) of the CXCL1-PWPI, PWPI and A2780 groups, but the invasion capacity of the CXCL1-PWPI group was significantly higher than that of the PWPI and A2780 groups (P < 0.05).

CONCLUSIONThe over-expression of CXCL1 gene may promote the proliferation and invasion ability of A2780 cells in vitro.

Cell Cycle ; Cell Line, Tumor ; Cell Movement ; Cell Proliferation ; Chemokine CXCL1 ; genetics ; metabolism ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Lentivirus ; genetics ; Neoplasm Invasiveness ; Neoplasms, Glandular and Epithelial ; genetics ; metabolism ; pathology ; Ovarian Neoplasms ; genetics ; metabolism ; pathology ; Plasmids ; RNA, Messenger ; metabolism ; Recombinant Proteins ; genetics ; metabolism ; Transfection

Epithelial ovarian cancers (EOCs) are highly lethal gynecological malignancies with a high recurrence rate. Therefore, developing prognostic markers for recurrence after chemotherapy is crucial for the treatment of ovarian cancers. As ovarian cancers frequently respond to DNA-damaging agents, we assessed the clinicopathological significance of key double-strand DNA break (DSB) repair genes, including BRCA1, BRCA2, BARD1, ATM, RAD51 and NBS1 in EOC cell lines and paraffin-embedded tissue sections from 140 EOC patients treated with cytoreductive surgery, followed by platinum-based chemotherapy. These samples were analyzed for the clinicopathological impact of DSB genes by western blot analysis, immunohistochemistry and quantitative real-time PCR. Of the DSB repair genes, BRCA1, ATM and NBS1, which are involved in the homologous recombination-mediated repair pathway, were related to aggressive parameters in EOC. When survival analysis was performed, NBS1 expression exhibited an association with EOC recurrence. Specifically, increased NBS1 expression was found in 107 out of 140 cases (76.0%) and correlated with advanced stage (P=0.001), high grade (P=0.001) and serous histology (P=0.008). The median recurrence-free survival in patients with positive and negative expression of NBS1 was 30 and 78 months, respectively (P=0.0068). In multivariate analysis, NBS1 was an independent prognostic factor for the recurrence of EOC. Together, these results suggest that NBS1 is a marker of poor prognosis for the recurrence of EOC and is associated with aggressive clinicopathological parameters.
Adolescent ; Adult ; Aged ; Biomarkers, Tumor/analysis/genetics ; Cell Cycle Proteins/analysis/*genetics ; Cell Line, Tumor ; *DNA Breaks, Double-Stranded ; *DNA Repair ; Female ; *Gene Expression Regulation, Neoplastic ; Humans ; Immunohistochemistry ; Middle Aged ; Neoplasms, Glandular and Epithelial/diagnosis/*genetics/*pathology ; Nuclear Proteins/analysis/*genetics ; Ovarian Neoplasms/diagnosis/*genetics/*pathology ; Ovary/metabolism/*pathology ; Prognosis ; Real-Time Polymerase Chain Reaction ; Young Adult

Adult ; Aged ; Female ; Fibroblast Growth Factor 1 ; genetics ; Fibroblast Growth Factor 2 ; genetics ; Humans ; Middle Aged ; Neoplasm Staging ; Neoplasms, Glandular and Epithelial ; metabolism ; pathology ; Ovarian Neoplasms ; metabolism ; pathology ; RNA, Messenger ; analysis ; Receptor Protein-Tyrosine Kinases ; genetics ; Receptor, Fibroblast Growth Factor, Type 1 ; Receptors, Fibroblast Growth Factor ; genetics